UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS KABI USA, LLC and FRESENIUS KABI SWISSBIOSIM GmbH Petitioners,

v.

AMGEN, INC. and AMGEN MANUFACTURING LIMITED Patent Owner.

IPR2020-00314

Patent No. 9,856,287

Title: REFOLDING PROTEINS USING A CHEMICALLY CONTROLLED REDOX STATE

PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,856,287 B1

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450



TABLE OF CONTENTS

				<u>Page</u>		
I.	INTE	RODU	JCTION	1		
II.	MANDATORY NOTICES					
	A.	Real Parties In Interest (§ 42.8(b)(1))				
	В.	Related Matters (§ 42.8(b)(2))				
	C.	Identification of Counsel (§ 42.8(b)(3)) and Service Information (§ 42.8(b)(4))				
III.	THE	THE BOARD SHOULD INSTITUTE REVIEW				
IV.	TECHNOLOGY BACKGROUND					
	A.	The	Basic Science of Proteins	11		
		1.	Protein Structure	11		
		2.	Protein Synthesis in and out of the Lab	11		
	B.	Reco	overy and Refolding of Expressed Protein	12		
		1.	Unfolding and Refolding of Recombinant Proteins	12		
		2.	Optimizing Redox Conditions	13		
	C.	Additional Considerations in Commercial Production of Recombinant Proteins				
V.	THE '287 PATENT, PROSECUTION HISTORY, AND RELATED PROCEEDINGS					
	A.	The	'287 Patent	16		
		1.	The Known Problem in the Art and the Alleged Innovative Solution	16		
		2.	The Scope of the Challenged Claims	19		
	B.	Pros	secution History	21		
	C.	The	Adello PGR	22		
	D.	The Board's Invalidation of Analogous Claims of the '138 Patent				
VI.	PERS	ERSON OF ORDINARY SKILL IN THE ART				
VII.	CLA	LAIM CONSTRUCTION				



TABLE OF CONTENTS (Continued)

				1 age
	A.	"Preparation"		
	В.	"Is Calculated"		
	C.	"Maintains Solubility"		
	D.	Defin	ned Claim Terms In Specification	26
IX.	IDENTIFICATION OF CHALLENGE AND RELIEF REQUESTED			26
	A.	Ground 1: Claims 1, 4, 8-10, 12, 14-16, 19, 23-26, 29-30 are anticipated by Vallejo (Ex. 1031)		
		1.	Claims 1, 10, 16, and 26	28
		2.	Claims 4, 12, 19 and 29	36
		3.	Claims 8, 9, 14, 15, 23, 24, 25 and 30	37
		4.	Claim Chart	38
	B.		and 2: Claims 16, 19-21, 23-26 and 29-30 are anticipated uddon (Ex. 1025)	42
		1.	Claims 16, and 26 are Anticipated by Ruddon	42
		2.	Claims 19 and 29 Are Anticipated by Ruddon	46
		3.	Claims 23, 24, 25 and 30 Are Anticipated By Ruddon	46
		4.	Claim Chart	48
	C.	are o	and 3: Claims 1, 4-6, 8-10, 12, 14-16, 19-21, 23-26, 29-30 byious over Ruddon in view of Clark 1998 in light of fer or Gilbert	51
		1.	Scope and Content of the Prior Art and Differences Between the Prior Art and the Challenged Claims	51
		2.	Motivation To Combine and Expectation of Success	57
		3.	Obviousness of the Independent Claims	59
		4.	Obviousness of Claims 4, 12, 19 and 29	62
		5.	Obviousness of Claims 5, 6, 20, and 21	63
		6.	Obviousness of Claims 8, 9, 14, 15, 23, 24, 25 and 30	64
	D.	Been	and 4: Claims 8, 9, 14, 15, 23, 24, 25 and 30 Would Have Obvious From Vallejo In Combination With Ruddon and	65



TABLE OF CONTENTS (Continued)

			Page
	E.	Secondary Considerations	66
D.	CONCLUSION		67



TABLE OF AUTHORITIES

Page	(S)
Cases	
Amgen Inc. et al. v. Tanvex BioPharma USA, Inc. et al., 19-cv-01374	3
Apotex Inc. v. Amgen Inc., IPR2016-01542, Paper 60 (PTAB Feb. 15, 2018) (Ex. 1038)	2
Choirock Contents Factory Co., Ltd., v. Spin Master Ltd., IPR2019-00897, Paper 17 (PTAB Sept. 26, 2019)	8
Cook Inc. et al., v. Medtronic, Inc., IPR2019-00123, Paper 11 (PTAB June 11, 2019)	8
Corning Optical Comm. RF, LLC, v. PPC Broadband, Inc., IPR2014-00440, IPR2014-00441	8
Foundation Medicine, Inc. v. Guardant Health, Inc., IPR2019-00652, Paper 12 (PTAB Aug. 19, 2019)	
Fresenius Kabi USA, LLC et al. v. Amgen, Inc. et al., IPR2019-00971, Paper 13 (PTAB Oct. 16, 2019)3, 4,	, 7
Fresenius Kabi USA, LLC et al. v. Amgen, Inc., IPR2019-01183, Paper 10 (PTAB Dec. 10, 2019)	11
General Plastic Indus. Co. v. Canon Kabushiki Kaisha, IPR2016-01357, Paper 19 (PTAB Sept. 6, 2017)	, 9
King Pharm., Inc. v. Eon Labs, Inc., 616 F.3d 1267 (Fed. Cir. 2010)	38
Lowes Cos. Inc., et al. v. Nichia Corp., IPR2017-02011, Paper 13 (PTAB Mar. 12, 2018)	6
PayPal, Inc. v. IOENGINE, LLC, IPR2019-00884, Paper 22 (PTAB Oct. 3, 2019)	8



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

